-
Mashup Score: 4ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities - 11 month(s) ago
https://www.globenewswire.com/news-release/2023/06/05/2681696/0/en/ITM-Announces-255m-Investment-Round-Plans-to-Advance-Radiopharmaceutical-Pipeline-and-to-Expand-Radioisotope-Production-Capacities.html?pdf=1
Source: www.itm-radiopharma.comCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0Passion for Precision - 11 month(s) ago
ITM Isotopen Technologien M
Source: www.itm-radiopharma.comCategories: Future of Medicine, Latest HeadlinesTweet-
📅 Connect with ITM’s CFO Dr. Klaus Maleck at #Jefferies Healthcare Conference in New York on Wednesday, June 7, 2023. Looking forward to meeting you and many valuable discussions. More about us at: https://t.co/mDNNWUwp1M https://t.co/cDHZUuYTKj
-
-
Mashup Score: 0
https://www.globenewswire.com/news-release/2023/04/27/2655976/0/en/ITM-Enters-Cooperation-Agreement-with-Paul-Scherrer-Institute-PSI-for-Co-Development-and-Upscaled-Manufacturing-of-Terbium-161-for-Theranostic-Application-in-Cancer.html?pdf=1
Source: www.itm-radiopharma.comCategories: Future of Medicine, Latest HeadlinesTweet-
Today we announced that ITM has entered into a cooperation agreement with the Paul Scherrer Institute (PSI) for the implementation of upscaled manufacturing of a novel therapeutic radionuclide, terbium-161. Read more at: https://t.co/bORfFwqOm0 https://t.co/NsYL4y5Z0s
-
-
Mashup Score: 0ITM Appoints Roger Estafanos as U.S. General Manager and Expands Presence with Opening of U.S. Headquarters in Princeton, New Jersey - 1 year(s) ago
https://www.globenewswire.com/news-release/2023/04/17/2647897/0/en/ITM-Appoints-Roger-Estafanos-as-U-S-General-Manager-and-Expands-Presence-with-Opening-of-U-S-Headquarters-in-Princeton-New-Jersey.html?pdf=1
Source: www.itm-radiopharma.comCategories: Future of Medicine, Latest HeadlinesTweet-
Today we announced that ITM has #opened its U.S. #headquarters in #Princeton, New Jersey and appointed Roger Estafanos as U.S. General Manager. Read more at: https://t.co/sgR6y0z2SZ https://t.co/TA2hs2Y9US
-
-
Mashup Score: 0Your Career at ITM - Precisely for You - 1 year(s) ago
Looking for a new job opportunity? The field of radiopharmaceuticals is rapidly expanding – and so are we. As a growing and globally active company, we are continuously looking for passionate, responsible and creative team-players with the ability to think outside the box. Join our dynamic, experienced and motivated team in managing highly complex tasks dealing with a wide variety of scientific…
Source: www.itm-radiopharma.comCategories: Future of Medicine, Latest HeadlinesTweet-
Exciting news! ITM has reached more than 500 employees as of April! 🎉 Join our team and help shape the future of Targeted Radionuclide Therapy. Apply now and be a part of our mission to revolutionize cancer treatment: https://t.co/6fRNpQSl9l #radiopharmaceuticals #wearehiring https://t.co/fTwvFafmvD
-
-
Mashup Score: 1ITM, Helmholtz Munich and University Hospital MĂĽnster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma - 1 year(s) ago
https://www.globenewswire.com/news-release/2023/03/13/2625497/0/en/ITM-Helmholtz-Munich-and-University-Hospital-M%C3%BCnster-Announce-Start-of-Phase-I-Clinical-Trial-with-Radiotherapeutic-ITM-31-for-Glioblastoma.html?pdf=1
Source: www.itm-radiopharma.comCategories: Future of Medicine, Latest HeadlinesTweet-
Today we announced the start of a phase I clinical trial with our radiotherapeutic drug candidate ITM-31. A novel Targeted Radionuclide Therapy candidate with non-carrier-added lutetium-177 for the treatment of malignant glioblastoma. More at: https://t.co/vcSDX0yBun https://t.co/Uere07QHS5
-
-
Mashup Score: 0
The numbers are alarming: in 2019, 502,655 people in Germany were diagnosed with cancer – 234,925 women and 267,730 men. These are the latest data from the Center for Cancer Registry Data (ZfKD) at the Robert Koch Institute (RKI). According to the data, about 4.6 million people in Germany currently have cancer, of which 2.55 million are women and 2.10 million are men. Due to improved survival…
Categories: Future of Medicine, Latest HeadlinesTweet-
Deutsche Börse Cash Market (@DBCashMarket) has published an overview article on German pharma and biotech companies active in oncology including radiopharmaceutical companies as ITM. Read the article “Oncology – new approaches to cancer therapy” at: https://t.co/AblyERrIuB https://t.co/TIvUc9YmDw
-
-
Mashup Score: 1ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs) - 2 year(s) ago
Garching / Munich, October 27, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for ITM-11 (n.c.a. 177Lu-edotreotide), an investigational radiopharmaceutical for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)….
Source: itm-radiopharma.comCategories: Future of Medicine, Latest HeadlinesTweet-
ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs). Read the full press release at: https://t.co/IHSORLKhw1 https://t.co/yDC3uwRxN6
-
-
Mashup Score: 0ITM: Isotope Production System Begins Commercial Production of Cancer-Fighting Lutetium-177 - 2 year(s) ago
ONTARIO, CANADA, and MUNICH, GERMANY , October 24, 2022 – An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company) and ITM Isotope Technologies Munich SE (ITM), announced today the commencement of commercial production of lutetium-177.   The announcement was celebrated at ITM’s headquarters in Munich, Germany, along with representatives of the partnership…
Source: itm-radiopharma.comCategories: Future of Medicine, Latest HeadlinesTweet-
We announced today together with our international partners @Bruce_Power and Isogen the commencement of commercial production of lutetium-177 at the novel Isotope Production System (IPS) in Bruce Power’s Unit 7. Read full press release at: https://t.co/cZyLKKRVx7 https://t.co/lVQdGdkZtv
-
-
Mashup Score: 1ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors - 2 year(s) ago
Exclusive license from Helmholtz Munich will enable ITM to access IP and know-how to develop and commercialize ITM-31 for glioblastoma patientsGarching / Munich, October 19, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel Targeted Radionuclide Therapy…
Source: itm-radiopharma.comCategories: Future of Medicine, Latest HeadlinesTweet-
Today ITM announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel #TargetedRadionuclideTherapy candidate for the treatment of malignant glioblastoma. Read the full press release at: https://t.co/9HTLTIgFJr https://t.co/Gxcd9kKMAd
-
📣 Exciting news! ITM announced equity investment round of €255m, plans to Advance #Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities. Read more at: https://t.co/qGBav9bqyO https://t.co/GD7mnukDFL